ABVXMore shares, more cash
Abivax just turned the dial all the way up on its offering. The company said underwriters fully exercised their option to purchase additional ADSs, bringing gross proceeds to $920 million (€807 million).
That’s the kind of number that makes a biotech treasury team breathe a little easier. Big cash piles can buy time, fund trials, and keep the lights on while the science does its thing. But for existing shareholders, there’s always a catch: more shares in the wild usually means a bigger slice of the pie being divided up.
Why investors care
This isn’t a science readout or an FDA win. It’s a capital raise — the financial equivalent of stocking the pantry before a long winter.
What you’re watching now:
- how Abivax plans to deploy the money
- whether the runway meaningfully improves
- how much dilution investors ultimately absorb
Big picture
For biotech names, cash is oxygen. A monster offering can look ugly in the moment, but it can also mean the company gets more shots on goal. The real question is whether Abivax turns that capital into data that actually moves the stock, not just the balance sheet.